NCT00246688View on ClinicalTrials.gov

Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Ovarian Neoplasms
Interventions
DRUG

Sagopilone (BAY86-5302 , ZK219477)

10.5 mg lyophilized sagopilone per vial

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00246688 - Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter